TickerFacts.

Polomar Health Services, Inc. (PMHS): Cost of Revenue

Annual figures by period end, from SEC filings.

$188.1K
Year ended 2025-12-31
$1.23M
Trailing 12 months to 2026-06-30
2023-12-31: $4.3K2024-12-31: $27.9K2025-12-31: $188.1K$188.1K
2023-12-31 Cost of Revenue (USD) 2025-12-31
Period endedCost of RevenueChange YoYSource filing
2025-12-31$188.1K+573.8%2026-05-06, From 2025-01-01
2024-12-31$27.9K+550.2%2026-05-06, From 2024-01-01
2023-12-31$4.3Kn/a2025-05-22, From 2023-01-01

Cost of Revenue at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCost of RevenueChange YoY
Polomar Health Services, Inc. (PMHS)2025-12-31$188.1K+573.8%
BioXcel Therapeutics, Inc. (BTAIQ)2025-12-31$164.0K-92.3%
Lexaria Bioscience Corp. (LEXX)2025-08-31$2.7K-43.6%
PMGC Holdings Inc. (ELAB)2025-12-31$404.8Kn/a
Silence Therapeutics plc (SLN)2025-12-31$215.0K-98.2%
Quantum Cyber N.V. (QUCY)2025-12-31$147.3K-53.8%
Onconetix, Inc. (ONCO)2025-12-31$182.5K-87.6%
Scienture Holdings, Inc. (SCNX)2025-12-31$100.1K-23.4%
60 Degrees Pharmaceuticals, Inc. (SXTP)2025-12-31$781.7K+103.2%

Compare PMHS, BTAIQ, LEXX, ELAB side by side · Screen every company in Pharmaceutical Preparations ↗